Hypoalbuminemia as a predictor of acute kidney injury during colistin treatment

Daniele Roberto Giacobbe, Alessandra di Masi, Loris Leboffe, Valerio Del Bono, Marianna Rossi, Dario Cappiello, Erika Coppo, Anna Marchese, Annarita Casulli, Alessio Signori, Andrea Novelli, Katja Perrone, Luigi Principe, Alessandra Bandera, Luca Enrico Vender, Andrea Misin, Pierpaolo Occhilupo, Marcello Melone, Paolo Ascenzi, Andrea GoriRoberto Luzzati, Claudio Viscoli, Stefano Di Bella

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

This study aimed to assess the predictors of acute kidney injury (AKI) during colistin therapy in a cohort of patients with bloodstream infections (BSI) due to colistin-susceptible Gram-negative bacteria, focusing on the role of serum albumin levels. The study consisted of two parts: (1) a multicentre retrospective clinical study to assess the predictors of AKI during colistin therapy, defined according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria; and (2) bioinformatic and biochemical characterization of the possible interaction between human serum albumin and colistin. Among the 170 patients included in the study, 71 (42%), 35 (21%), and 11 (6%) developed KDIGO stage 1 (K1-AKI), KDIGO stage 2 (K2-AKI), and KDIGO stage 3 (K3-AKI), respectively. In multivariable analyses, serum albumin <2.5 g/dL was independently associated with K1-AKI (subdistribution hazard ratio [sHR] 1.85, 95% confidence interval [CI] 1.17–2.93, p = 0.009) and K2-AKI (sHR 2.37, 95% CI 1.15–4.87, p = 0.019). Bioinformatic and biochemical analyses provided additional information nurturing the discussion on how hypoalbuminemia favors development of AKI during colistin therapy. In conclusion, severe hypoalbuminemia independently predicted AKI during colistin therapy in a large cohort of patients with BSI due to colistin-susceptible Gram-negative bacteria. Further study is needed to clarify the underlying causal pathways.

Original languageEnglish
Article number11968
JournalScientific Reports
Volume8
Issue number1
DOIs
Publication statusPublished - Dec 1 2018

Fingerprint

Colistin
Hypoalbuminemia
Acute Kidney Injury
Kidney Diseases
Serum Albumin
Therapeutics
Computational Biology
Gram-Negative Bacteria
Confidence Intervals
Infection
Retrospective Studies

ASJC Scopus subject areas

  • General

Cite this

Giacobbe, D. R., di Masi, A., Leboffe, L., Del Bono, V., Rossi, M., Cappiello, D., ... Di Bella, S. (2018). Hypoalbuminemia as a predictor of acute kidney injury during colistin treatment. Scientific Reports, 8(1), [11968]. https://doi.org/10.1038/s41598-018-30361-5

Hypoalbuminemia as a predictor of acute kidney injury during colistin treatment. / Giacobbe, Daniele Roberto; di Masi, Alessandra; Leboffe, Loris; Del Bono, Valerio; Rossi, Marianna; Cappiello, Dario; Coppo, Erika; Marchese, Anna; Casulli, Annarita; Signori, Alessio; Novelli, Andrea; Perrone, Katja; Principe, Luigi; Bandera, Alessandra; Vender, Luca Enrico; Misin, Andrea; Occhilupo, Pierpaolo; Melone, Marcello; Ascenzi, Paolo; Gori, Andrea; Luzzati, Roberto; Viscoli, Claudio; Di Bella, Stefano.

In: Scientific Reports, Vol. 8, No. 1, 11968, 01.12.2018.

Research output: Contribution to journalArticle

Giacobbe, DR, di Masi, A, Leboffe, L, Del Bono, V, Rossi, M, Cappiello, D, Coppo, E, Marchese, A, Casulli, A, Signori, A, Novelli, A, Perrone, K, Principe, L, Bandera, A, Vender, LE, Misin, A, Occhilupo, P, Melone, M, Ascenzi, P, Gori, A, Luzzati, R, Viscoli, C & Di Bella, S 2018, 'Hypoalbuminemia as a predictor of acute kidney injury during colistin treatment', Scientific Reports, vol. 8, no. 1, 11968. https://doi.org/10.1038/s41598-018-30361-5
Giacobbe, Daniele Roberto ; di Masi, Alessandra ; Leboffe, Loris ; Del Bono, Valerio ; Rossi, Marianna ; Cappiello, Dario ; Coppo, Erika ; Marchese, Anna ; Casulli, Annarita ; Signori, Alessio ; Novelli, Andrea ; Perrone, Katja ; Principe, Luigi ; Bandera, Alessandra ; Vender, Luca Enrico ; Misin, Andrea ; Occhilupo, Pierpaolo ; Melone, Marcello ; Ascenzi, Paolo ; Gori, Andrea ; Luzzati, Roberto ; Viscoli, Claudio ; Di Bella, Stefano. / Hypoalbuminemia as a predictor of acute kidney injury during colistin treatment. In: Scientific Reports. 2018 ; Vol. 8, No. 1.
@article{fa93169b090846d8ac88a48d421e3b09,
title = "Hypoalbuminemia as a predictor of acute kidney injury during colistin treatment",
abstract = "This study aimed to assess the predictors of acute kidney injury (AKI) during colistin therapy in a cohort of patients with bloodstream infections (BSI) due to colistin-susceptible Gram-negative bacteria, focusing on the role of serum albumin levels. The study consisted of two parts: (1) a multicentre retrospective clinical study to assess the predictors of AKI during colistin therapy, defined according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria; and (2) bioinformatic and biochemical characterization of the possible interaction between human serum albumin and colistin. Among the 170 patients included in the study, 71 (42{\%}), 35 (21{\%}), and 11 (6{\%}) developed KDIGO stage 1 (K1-AKI), KDIGO stage 2 (K2-AKI), and KDIGO stage 3 (K3-AKI), respectively. In multivariable analyses, serum albumin <2.5 g/dL was independently associated with K1-AKI (subdistribution hazard ratio [sHR] 1.85, 95{\%} confidence interval [CI] 1.17–2.93, p = 0.009) and K2-AKI (sHR 2.37, 95{\%} CI 1.15–4.87, p = 0.019). Bioinformatic and biochemical analyses provided additional information nurturing the discussion on how hypoalbuminemia favors development of AKI during colistin therapy. In conclusion, severe hypoalbuminemia independently predicted AKI during colistin therapy in a large cohort of patients with BSI due to colistin-susceptible Gram-negative bacteria. Further study is needed to clarify the underlying causal pathways.",
author = "Giacobbe, {Daniele Roberto} and {di Masi}, Alessandra and Loris Leboffe and {Del Bono}, Valerio and Marianna Rossi and Dario Cappiello and Erika Coppo and Anna Marchese and Annarita Casulli and Alessio Signori and Andrea Novelli and Katja Perrone and Luigi Principe and Alessandra Bandera and Vender, {Luca Enrico} and Andrea Misin and Pierpaolo Occhilupo and Marcello Melone and Paolo Ascenzi and Andrea Gori and Roberto Luzzati and Claudio Viscoli and {Di Bella}, Stefano",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41598-018-30361-5",
language = "English",
volume = "8",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Hypoalbuminemia as a predictor of acute kidney injury during colistin treatment

AU - Giacobbe, Daniele Roberto

AU - di Masi, Alessandra

AU - Leboffe, Loris

AU - Del Bono, Valerio

AU - Rossi, Marianna

AU - Cappiello, Dario

AU - Coppo, Erika

AU - Marchese, Anna

AU - Casulli, Annarita

AU - Signori, Alessio

AU - Novelli, Andrea

AU - Perrone, Katja

AU - Principe, Luigi

AU - Bandera, Alessandra

AU - Vender, Luca Enrico

AU - Misin, Andrea

AU - Occhilupo, Pierpaolo

AU - Melone, Marcello

AU - Ascenzi, Paolo

AU - Gori, Andrea

AU - Luzzati, Roberto

AU - Viscoli, Claudio

AU - Di Bella, Stefano

PY - 2018/12/1

Y1 - 2018/12/1

N2 - This study aimed to assess the predictors of acute kidney injury (AKI) during colistin therapy in a cohort of patients with bloodstream infections (BSI) due to colistin-susceptible Gram-negative bacteria, focusing on the role of serum albumin levels. The study consisted of two parts: (1) a multicentre retrospective clinical study to assess the predictors of AKI during colistin therapy, defined according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria; and (2) bioinformatic and biochemical characterization of the possible interaction between human serum albumin and colistin. Among the 170 patients included in the study, 71 (42%), 35 (21%), and 11 (6%) developed KDIGO stage 1 (K1-AKI), KDIGO stage 2 (K2-AKI), and KDIGO stage 3 (K3-AKI), respectively. In multivariable analyses, serum albumin <2.5 g/dL was independently associated with K1-AKI (subdistribution hazard ratio [sHR] 1.85, 95% confidence interval [CI] 1.17–2.93, p = 0.009) and K2-AKI (sHR 2.37, 95% CI 1.15–4.87, p = 0.019). Bioinformatic and biochemical analyses provided additional information nurturing the discussion on how hypoalbuminemia favors development of AKI during colistin therapy. In conclusion, severe hypoalbuminemia independently predicted AKI during colistin therapy in a large cohort of patients with BSI due to colistin-susceptible Gram-negative bacteria. Further study is needed to clarify the underlying causal pathways.

AB - This study aimed to assess the predictors of acute kidney injury (AKI) during colistin therapy in a cohort of patients with bloodstream infections (BSI) due to colistin-susceptible Gram-negative bacteria, focusing on the role of serum albumin levels. The study consisted of two parts: (1) a multicentre retrospective clinical study to assess the predictors of AKI during colistin therapy, defined according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria; and (2) bioinformatic and biochemical characterization of the possible interaction between human serum albumin and colistin. Among the 170 patients included in the study, 71 (42%), 35 (21%), and 11 (6%) developed KDIGO stage 1 (K1-AKI), KDIGO stage 2 (K2-AKI), and KDIGO stage 3 (K3-AKI), respectively. In multivariable analyses, serum albumin <2.5 g/dL was independently associated with K1-AKI (subdistribution hazard ratio [sHR] 1.85, 95% confidence interval [CI] 1.17–2.93, p = 0.009) and K2-AKI (sHR 2.37, 95% CI 1.15–4.87, p = 0.019). Bioinformatic and biochemical analyses provided additional information nurturing the discussion on how hypoalbuminemia favors development of AKI during colistin therapy. In conclusion, severe hypoalbuminemia independently predicted AKI during colistin therapy in a large cohort of patients with BSI due to colistin-susceptible Gram-negative bacteria. Further study is needed to clarify the underlying causal pathways.

UR - http://www.scopus.com/inward/record.url?scp=85051459098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051459098&partnerID=8YFLogxK

U2 - 10.1038/s41598-018-30361-5

DO - 10.1038/s41598-018-30361-5

M3 - Article

AN - SCOPUS:85051459098

VL - 8

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 11968

ER -